PAG
ANTX icon

Private Advisor Group’s AN2 Therapeutics ANTX Stock Holding History

Private Advisor Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.8K Sell
12,500
-10,000
-44% -$20.6K ﹤0.01% 2588
2025
Q4 		$25.6K Hold
22,500
– – ﹤0.01% 2551
2025
Q3 		$28.6K Hold
22,500
– – ﹤0.01% 2483
2025
Q2 		$23.9K Hold
22,500
– – ﹤0.01% 2390
2025
Q1 		$30.6K Hold
22,500
– – ﹤0.01% 2254
2024
Q4 		$31.1K Hold
22,500
– – ﹤0.01% 2233
2024
Q3 		$24.1K Hold
22,500
– – ﹤0.01% 2368
2024
Q2 		$48.4K Hold
22,500
– – ﹤0.01% 2277
2024
Q1 		$73.1K Buy
+22,500
New +$245K ﹤0.01% 2226
2023
Q3 		– Sell
-67,500
Closed -$574K – 2294
2023
Q2 		$574K Buy
67,500
+45,492
+207% +$327K 0.01% 1308
2023
Q1 		$217K Buy
22,008
+11,000
+100% +$122K ﹤0.01% 1755
2022
Q4 		$105 Buy
+11,008
New +$147K ﹤0.01% 1577
2022
Q3 		– Sell
-11,001
Closed -$165K – 1923
2022
Q2 		$165K Buy
+11,001
New +$146K ﹤0.01% 1882

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Private Advisor Group's ANTX Position: Q1 2026 in Review

Private Advisor Group reduced its AN2 Therapeutics (ANTX) stake by 44% in Q1 2026, selling an estimated $20.6K and leaving 12,500 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2588.

Private Advisor Group first reported a position in ANTX in Q2 2022 and has held it in 13 quarters since. The position peaked at $574K in Q2 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Private Advisor Group held 12,500 shares of AN2 Therapeutics worth $42.8K as of Q1 2026.
  • Private Advisor Group sold 10,000 AN2 Therapeutics shares in Q1 2026, an estimated $20.6K.
  • AN2 Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q1 2026, its #2588 holding.
  • Private Advisor Group first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 13 quarters since.
  • Private Advisor Group's AN2 Therapeutics position peaked at $574K in Q2 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.